Cargando…

Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma

Glioblastoma (GBM) is the most common and highly lethal type of brain tumor, with poor survival despite advances in understanding its complexity. After current standard therapeutic treatment, including tumor resection, radiotherapy and concomitant chemotherapy with temozolomide, the median overall s...

Descripción completa

Detalles Bibliográficos
Autores principales: Drakulic, Danijela, Schwirtlich, Marija, Petrovic, Isidora, Mojsin, Marija, Milivojevic, Milena, Kovacevic-Grujicic, Natasa, Stevanovic, Milena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406959/
https://www.ncbi.nlm.nih.gov/pubmed/36010607
http://dx.doi.org/10.3390/cells11162530
_version_ 1784774248804384768
author Drakulic, Danijela
Schwirtlich, Marija
Petrovic, Isidora
Mojsin, Marija
Milivojevic, Milena
Kovacevic-Grujicic, Natasa
Stevanovic, Milena
author_facet Drakulic, Danijela
Schwirtlich, Marija
Petrovic, Isidora
Mojsin, Marija
Milivojevic, Milena
Kovacevic-Grujicic, Natasa
Stevanovic, Milena
author_sort Drakulic, Danijela
collection PubMed
description Glioblastoma (GBM) is the most common and highly lethal type of brain tumor, with poor survival despite advances in understanding its complexity. After current standard therapeutic treatment, including tumor resection, radiotherapy and concomitant chemotherapy with temozolomide, the median overall survival of patients with this type of tumor is less than 15 months. Thus, there is an urgent need for new insights into GBM molecular characteristics and progress in targeted therapy in order to improve clinical outcomes. The literature data revealed that a number of different signaling pathways are dysregulated in GBM. In this review, we intended to summarize and discuss current literature data and therapeutic modalities focused on targeting dysregulated signaling pathways in GBM. A better understanding of opportunities for targeting signaling pathways that influences malignant behavior of GBM cells might open the way for the development of novel GBM-targeted therapies.
format Online
Article
Text
id pubmed-9406959
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94069592022-08-26 Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma Drakulic, Danijela Schwirtlich, Marija Petrovic, Isidora Mojsin, Marija Milivojevic, Milena Kovacevic-Grujicic, Natasa Stevanovic, Milena Cells Review Glioblastoma (GBM) is the most common and highly lethal type of brain tumor, with poor survival despite advances in understanding its complexity. After current standard therapeutic treatment, including tumor resection, radiotherapy and concomitant chemotherapy with temozolomide, the median overall survival of patients with this type of tumor is less than 15 months. Thus, there is an urgent need for new insights into GBM molecular characteristics and progress in targeted therapy in order to improve clinical outcomes. The literature data revealed that a number of different signaling pathways are dysregulated in GBM. In this review, we intended to summarize and discuss current literature data and therapeutic modalities focused on targeting dysregulated signaling pathways in GBM. A better understanding of opportunities for targeting signaling pathways that influences malignant behavior of GBM cells might open the way for the development of novel GBM-targeted therapies. MDPI 2022-08-15 /pmc/articles/PMC9406959/ /pubmed/36010607 http://dx.doi.org/10.3390/cells11162530 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Drakulic, Danijela
Schwirtlich, Marija
Petrovic, Isidora
Mojsin, Marija
Milivojevic, Milena
Kovacevic-Grujicic, Natasa
Stevanovic, Milena
Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma
title Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma
title_full Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma
title_fullStr Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma
title_full_unstemmed Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma
title_short Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma
title_sort current opportunities for targeting dysregulated neurodevelopmental signaling pathways in glioblastoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406959/
https://www.ncbi.nlm.nih.gov/pubmed/36010607
http://dx.doi.org/10.3390/cells11162530
work_keys_str_mv AT drakulicdanijela currentopportunitiesfortargetingdysregulatedneurodevelopmentalsignalingpathwaysinglioblastoma
AT schwirtlichmarija currentopportunitiesfortargetingdysregulatedneurodevelopmentalsignalingpathwaysinglioblastoma
AT petrovicisidora currentopportunitiesfortargetingdysregulatedneurodevelopmentalsignalingpathwaysinglioblastoma
AT mojsinmarija currentopportunitiesfortargetingdysregulatedneurodevelopmentalsignalingpathwaysinglioblastoma
AT milivojevicmilena currentopportunitiesfortargetingdysregulatedneurodevelopmentalsignalingpathwaysinglioblastoma
AT kovacevicgrujicicnatasa currentopportunitiesfortargetingdysregulatedneurodevelopmentalsignalingpathwaysinglioblastoma
AT stevanovicmilena currentopportunitiesfortargetingdysregulatedneurodevelopmentalsignalingpathwaysinglioblastoma